|Other Names||Pirin, Probable quercetin 2, 3-dioxygenase PIR, Probable quercetinase, PIR|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7619c was selected from the Center region of human PIR. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Transcriptional coregulator of NF-kappa-B which facilitates binding of NF-kappa-B proteins to target kappa-B genes in a redox-state-dependent manner. May be required for efficient terminal myeloid maturation of hematopoietic cells. Has quercetin 2,3-dioxygenase activity (in vitro).|
|Cellular Location||Nucleus. Cytoplasm. Note=Predominantly localized in dot-like subnuclear structures. Cytoplasmic localization of PIR seems to positively correlate with melanoma progression|
|Tissue Location||Highly expressed in a subset of melanomas. Detected at very low levels in most tissues (at protein level) Expressed in all tissues, with highest level of expression in heart and liver.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PIR is a member of the cupin superfamily. The protein is an Fe(II)-containing nuclear protein expressed in all tissues of the body and concentrated within dot-like subnuclear structures. Interactions with nuclear factor I/CCAAT box transcription factor as well as B cell lymphoma 3-encoded oncoprotein suggest the protein may act as a transcriptional cofactor and be involved in the regulation of DNA transcription and replication.
Zeng,Q., Li,X. Acta Crystallogr. D Biol. Crystallogr. 59 (PT 8), 1496-1498 (2003)Pang,H., Bartlam,M. J. Biol. Chem. 279 (2), 1491-1498 (2004)Wendler,W.M., Kremmer,E. J. Biol. Chem. 272 (13), 8482-8489 (1997)
If you have any additional inquiries please email technical services at email@example.com.